Accordingly, C16:0 and C22:0/24:0 ceramides should be further studied as potential resistance biomarkers, and their potential benefits in monitoring therapeutic efficacy of vemurafenib in BRAF mutant colon cancer should be further explored. This evidence concerns the gene BRAF and colonic neoplasm.